Other live channels you can watch Welcome and Opening of the Biotech Atelier Advanced therapy medicinal products (ATMPs) Digital Health and Artificial Intelligence Real-World Evidence (RWE) and HTA Personalized Medicine: Recent Developments Personalized Medicine: Biomarkers Human Capital in “Corona Times” and beyond The Life Science Funding in “Corona Times” and beyond Biotechnology Innovation and Investment – Before, Now and Then Innovations in the COVID-19 Era Artificial Intelligence in the COVID-19 Era Personalized Medicine: Biobanking and Population Genetics Future of clinical trials, AI and data Personalization, Pharmacogenetics and Pharmacogenomics Innovation in Medicine – ATMPs How Germany managed the coronavirus crisis Regulatory Challenges in the COVID Era Medical Cannabis – the Wonder Substance Hospital Exemption for ATMPs Medical Devices in the Digital Health Era COVID-19: the New Reality in Bulgaria and Worldwide COVID-19 Diagnostic and Therapy, the Bulgarian Perspective COVID-19 Diagnostics: Hear the Experts Water and Biotechnologies Plant Biotechnology: Beyond Healthcare and Pharma Dynamics, 2020 Precision Medicine’s Potential and Current Gaps ATMPs, patient’s perspective ATMPs, Leveraging the Digital Supply Chain IBM Solutions in Healthcare The Supercomputers – modern accelerators of innovation in healthcare Beyond healthcare system towards a health-tech ecosystem 3D Bioprinting? (CTI Biotech) Big Data and AI in Digital Health BDADH – GATE Institute – Research areas and application themes BDADH – Session 2 opening BDADH – Session 1 opening BDADH – Detecting and characterizing complex variation in the human genome sequence that can affect brain function BDADH – Non-invasive biomarker detection, identification, and computational modeling for neonatal health BDADH – Leveraging AI and RWE Big Data to Develop Novel Multi-omic AI Diagnostic Test for Immuno-Oncology Therapy in Lung Cancer BDADH – Session 2 opening BDADH – Clinical aspects of dementia management and follow-up in Bulgaria and opportunities for digitalisation BDADH – Digital twin modelling of patients with cognitive disorders Healthtech and Biotech startup track PBB – The future of plant agriculture PBB – Will computational biology push the next breakthrough in plant biotechnology and breeding? FCTAID – Welcome and opening FCTAID – Setting the scene: Future of clinical trials – what it would be? FCTAID – Clinical Research Landscape in Bulgaria – From Status Quo toward Status GO! FCTAID – Clinical Trials market & Financial impact – Global overview FCTAID – Scientific evidence based ethical assessment. Future objectives of national ethics committee. FCTAID – The lack of data as an obstacle to the clinical trials development in CEE FCTAID – Patient-centric software powering decentralised trials FCTAID – Research transparency, public involvement and proportionality of ethical review FCTAID – Activities of the Ethics Committee for Clinical Trials in Bulgaria to meet the challenges of the new regulatory requirements in the EU and to improve the environment for conducting clinical trials in Bulgaria FCTAID – Decentralised clinical trials: moving from nicety to necessity FCTAID – High level overview of several digital innovations and technologies that help advance healthcare research and clinical care FCTAID – NIHR Clinical Research Network: the delivery arm of the NHS FCTAID – How to embed research in a national health service FCTAID – Clinical Trials in Bulgaria – Key Challenges FCTAID – Sleep disorders and clinical trials: new challenges and perspectives FCTAID – At a time of a global pandemic we recognize more than ever the need for clinical research- key note on the importance, benefits and socio-economic impact of clinical trials FCTAID – Romanian clinical trials market – huge potential suffocated by lack of vision FCTAID – The importance of clinical research in saving patient’s life – academy point of view FCTAID – Improved adverse event/medical error reporting FCTAID – Conclusions and closure FCTAID – Using AI to generate Real World Evidence (RWE) PPP – Welcome and Opening PPP – Personalized Medicine – the New Reality in Medical School? PPP – Moving from disease treatment to disease prevention – personalization is the key PPP – Implementation of Pharmacogenetic testing: what are the priorities? PPP – Pharmacogenetics in oncology clinical practice PPP – Progressing a data driven healthcare system PPP – Donor-derived cell-free DNA testing in organ transplantation: a value proposition PPP – Enhancing Precision Medicine and Pharmacogenetics through Clinical Mass Spectrometry Platform PPP – Rational Cancer Therapy PPP – Closing discussion and remarks ATMPs – EU ATMP development landscape and outlook ATMPs – ATMP update and Regulatory Strategy ATMPs – Nonclinical Challenges and Cases with ATMPs ATMPs – CMC Challenges and case studies with ATMPs ATMPs – The ATMP post approval path – patient and market access ATMPs – Riding the clinical trial rollercoaster – a patient’s perspective FCTAID – Patient First: changing the clinical trials paradigm IRI – Research infrastructures: Why do we need them? IRI – Covid – what can infrastructures do going forward IRI – Infrastructures Role in developing Personalized Health Potable water and biotechnologies Topic for the near future: Water microbiome Wastewater and Biotechnologies The future of the water sector: Matching needs and technologies Potable Water and Biotechnologies Wastewater and Biotechnologies Lunch and networking time The Future of the Water Sector – Matching Needs and Technologies Genomics and data to support personalised medicine (incl. registers/biobanks, biomarkers assessment) Discussion panel with Q&A from the audience Adoption of personalised medicine (incl. patient centricity, health technology assessment, regulations) Discussion panel with Q&A from the audience Personalised medicine – what the future brings? Discussion panel with Q&A from the audience Welcome and Opening of the Biotech Atelier Movement Health 2030: the Future of Healthcare The Innovative Health Initiative – Europe’s new public private partnership in health The Microbiome and Nutrigenetics Non-invasive Prenatal and Neonatal Testing Lifestyle and Health Advances Psychiatry: Pharmacogenetics and Personalised Practices Assisted reproductive technology (ART) Social freezing not cost effective to the society Problems with Using Polygenic Scores to Select Embryos Where are we now? Did CSV keep its promises? Advances in Diagnosis and Management of ATTR amyloid cardiomyopathy The Value of Patient Centricity – Why the Patient Voice is Essential Digital Health: Supporting Health Through Technologies Digital Solutions to Healthcare Problems HIV – The neglected pandemic Quality Assurance in a Molecualr Food Testing laboratory (an overview) Human Genetics in Favor of Reliable Diagnostics The Role of biomarkers in Personalised Medicine Precision medicine in daily routine, face reality Impact of access to biomarker test on the patient pathway Advantages of automated and digital Tissue Engineering and 3D cell cultivation Data Platforms for Digital Health DTx – AI as a medical device DTx – DTx in Cancer Treatment DTx – Health Equality Through Innovation DTx – DTx in Neuroscience The Potential of Gene Therapy for People with Rare Genetic Disorders Movement Health 2030 – Central and Eastern Europe (CEE) Movement Health 2030 – Bulgaria Wastewater and Antimicrobial Resistance The Concept and Value of Patient Advocacy My Stage IV Cancer Journey… And what helped me through it Towards a patient-centred approach in cancer care The value of patient advocacy in the field of oncology Prevention in Action – Cervical Cancer Cancer Registers – first steps: Armenia, Brazil and Kenya Pancreatic Cancer – increasing pancreatic cancer awareness Pain management – pancreatic cancer Inspire2Live and International Agency for Research in Cancer (IARC) partnership and collaboration Dicsussion and Conclusion Personalised Medicine and Patient Advocacy The Intersection of a Science Background and Patient Advocacy: How I Became a Better Advocate Don’t let Cancer become the Forgotten “C” in the Fight against COVID-19 COVID-19 vaccination for Cancer Patients How to fund your life science/biotech startup with non-dilutive funding Menopause and Employment – the Law AHT – HIV – the Neglected Pandemic AHT – Human Genetics in Favor of Reliable Diagnostics AHT – Wastewater and Antimicrobial Resistance PM – The Microbiome and Nutrigenetics PM – Non-invasive Prenatal and Neonatal Testing PM – Lifestyle and Health Advances PM – Kip Olmstead Keynote PM – Psychiatry: Pharmacogenetics and Personalised Practices PM – Neurology: precision medicine and management AHT – Opening / Introduction CSV – Validating AI/ML Solutions CSV – CSV and Best Practices GATE – GATE Flagship project on Alzheimer Validating AI/ML Solutions Personalised Medicine – building bridges among patients, researchers, decision makers & industry GATE – GATE Data platform GATE – Privacy-preserving AI-based diagnostic tools for Alzheimer disease Panel discussion “Water Resources and Biotechnologies” Biohydrogel – Saving irrigation water and protecting crops from droughts Environmental taxes and Water discharge fees Panel discussion “Wastewater and Biotechnologies” Anaerobic treatment for wastewater Panel discussion “Artificial intelligence and Water” Developing a one health approach by using a multi-dimensional matrix Digital Mental Health in 2022 and beyond IHI: Europe’s New public-private partnership for health and innovation Human Genetics and Personalised Medicine Personalised medicine strategies and application: genomics and molecular medicine ATMPs – a promise for better health and care Biotech and Life Science Clusters – space for innovation, development and business Digital Female Health in 2022 DTx – KPIs, Growth, reach, conversion, active engagement DTx Leaders of the NORDICS Regulation of DTx in the NORDICS Challenges in Digital Mental Health DHL: support of business and R&D Welcome and Opening of the Biotech Atelier Healthcare in Europe: what does the future hold? FemTech Leaders and the Gender Health Gap ATMPs and Rare Diseases: Patient Access and Opportunities New Perspectives in Pharmacogenetics and Pharmacogenomics Patient Centrricity and Patient Advocacy – What is Behind the Terms Patient centric medicines’ development: advancing meaningful patient engagement in the life cycle of medicines for better health outcomes EUPATI European Patients’ Academy on Therapeutic Innovation Preferences – an evidence-based approach to include patient perspectives in medical decision-making Patient Centricity: the Perspective of Institutions and Initiatives Fireside Chat: Patient Advocacy – What Is It? All for One, One for All: Patient Advocacy in Different Disease Areas / Patient Advocacy – United around a Common Mission War On Cancer: the Community for Everyone Impacted by Cancer Patient Advocacy and Healthcare Industry – the Meeting Point Patient Centricity and Patient Advocacy: the Industry Perspective The Importance of Diversity, Equity, and Inclusion in Advocacy Groups and its Effect on Patient Access for Rare Diseases in the Hispanic Community Moving Beyond Population Averages: Patients’ Priorities for Advancing Personalized Medicine Digital Health and Therapeutics: The New Reality Delightful future of healthcare DTx Takeaways from Germany, UK, Belgium, NORDICS Demystifying Health Coaching: Why and how to leverage these behavior change agents to surround your DTx Love problem: solve, validate, iterate, repeat The global mental health crisis No patient left behind: digital health and health inequalities Implementing the EU digital health strategy Take a selfie, know your healthie Leveraging data for better health Connection in the loneliness pandemic Spurring DTx innovation – a cross-country take The European DTx policy coalition Maximizing Your ‘Attractiveness Quotient’ Digitalizing healthcare: putting the full puzzle together, Roche An advice to my younger self, HelloBetter How the Cloud, Machine Learning and High Performance Computing are transforming Healthcare and Life Sciences Innovation Learning to ride the Lion – Clinician to Entrepreneur Secret sauce for accelerating innovation Healing the unhealable wound Our own little secret, Grace.Health Collaboration & integration: together, stronger, Augmental Technologies Closing of Digital Therapeutics & Digital Health Opening Introduction, key notes EU-QPPV – legal background and qualifications for the QPPV role; PV System oversight The EU Pharmacovigilance System Master File (PSMF) Pharmacovigilance System Master File (PSMF) – annexes, local PSMF, summary Audits and inspections of PV system QPPV Oversight & Compliance Management Medical Devices: Innovations and Regulation Fair data in life sciences Seizing the Digital Biomarker in DTx: trends, applications and opportunities, Evocal Health Pharmas & DTx, a new business model paradigm How to DTx: Pharma & biotech options for engaging with digital therapeutics – buy, build or partner to build Water and antimicrobial resistance Residual antibiotics in water Keynote lecture “Antimicrobial resistance in water: explore, measure and monitor” by Maarten van Dongen, AMR Insights Wastewater treatment and water re-use Interview “Water and EU Regulations” Closing of “Water & Biotechnologies” Keynote lecture topic TBA
Welcome and Opening of the Biotech Atelier Advanced therapy medicinal products (ATMPs) Digital Health and Artificial Intelligence Real-World Evidence (RWE) and HTA Personalized Medicine: Recent Developments Personalized Medicine: Biomarkers Human Capital in “Corona Times” and beyond The Life Science Funding in “Corona Times” and beyond Biotechnology Innovation and Investment – Before, Now and Then Innovations in the COVID-19 Era Artificial Intelligence in the COVID-19 Era Personalized Medicine: Biobanking and Population Genetics Future of clinical trials, AI and data Personalization, Pharmacogenetics and Pharmacogenomics Innovation in Medicine – ATMPs How Germany managed the coronavirus crisis Regulatory Challenges in the COVID Era Medical Cannabis – the Wonder Substance Hospital Exemption for ATMPs Medical Devices in the Digital Health Era COVID-19: the New Reality in Bulgaria and Worldwide COVID-19 Diagnostic and Therapy, the Bulgarian Perspective COVID-19 Diagnostics: Hear the Experts Water and Biotechnologies Plant Biotechnology: Beyond Healthcare and Pharma Dynamics, 2020 Precision Medicine’s Potential and Current Gaps ATMPs, patient’s perspective ATMPs, Leveraging the Digital Supply Chain IBM Solutions in Healthcare The Supercomputers – modern accelerators of innovation in healthcare Beyond healthcare system towards a health-tech ecosystem 3D Bioprinting? (CTI Biotech) Big Data and AI in Digital Health BDADH – GATE Institute – Research areas and application themes BDADH – Session 2 opening BDADH – Session 1 opening BDADH – Detecting and characterizing complex variation in the human genome sequence that can affect brain function BDADH – Non-invasive biomarker detection, identification, and computational modeling for neonatal health BDADH – Leveraging AI and RWE Big Data to Develop Novel Multi-omic AI Diagnostic Test for Immuno-Oncology Therapy in Lung Cancer BDADH – Session 2 opening BDADH – Clinical aspects of dementia management and follow-up in Bulgaria and opportunities for digitalisation BDADH – Digital twin modelling of patients with cognitive disorders Healthtech and Biotech startup track PBB – The future of plant agriculture PBB – Will computational biology push the next breakthrough in plant biotechnology and breeding? FCTAID – Welcome and opening FCTAID – Setting the scene: Future of clinical trials – what it would be? FCTAID – Clinical Research Landscape in Bulgaria – From Status Quo toward Status GO! FCTAID – Clinical Trials market & Financial impact – Global overview FCTAID – Scientific evidence based ethical assessment. Future objectives of national ethics committee. FCTAID – The lack of data as an obstacle to the clinical trials development in CEE FCTAID – Patient-centric software powering decentralised trials FCTAID – Research transparency, public involvement and proportionality of ethical review FCTAID – Activities of the Ethics Committee for Clinical Trials in Bulgaria to meet the challenges of the new regulatory requirements in the EU and to improve the environment for conducting clinical trials in Bulgaria FCTAID – Decentralised clinical trials: moving from nicety to necessity FCTAID – High level overview of several digital innovations and technologies that help advance healthcare research and clinical care FCTAID – NIHR Clinical Research Network: the delivery arm of the NHS FCTAID – How to embed research in a national health service FCTAID – Clinical Trials in Bulgaria – Key Challenges FCTAID – Sleep disorders and clinical trials: new challenges and perspectives FCTAID – At a time of a global pandemic we recognize more than ever the need for clinical research- key note on the importance, benefits and socio-economic impact of clinical trials FCTAID – Romanian clinical trials market – huge potential suffocated by lack of vision FCTAID – The importance of clinical research in saving patient’s life – academy point of view FCTAID – Improved adverse event/medical error reporting FCTAID – Conclusions and closure FCTAID – Using AI to generate Real World Evidence (RWE) PPP – Welcome and Opening PPP – Personalized Medicine – the New Reality in Medical School? PPP – Moving from disease treatment to disease prevention – personalization is the key PPP – Implementation of Pharmacogenetic testing: what are the priorities? PPP – Pharmacogenetics in oncology clinical practice PPP – Progressing a data driven healthcare system PPP – Donor-derived cell-free DNA testing in organ transplantation: a value proposition PPP – Enhancing Precision Medicine and Pharmacogenetics through Clinical Mass Spectrometry Platform PPP – Rational Cancer Therapy PPP – Closing discussion and remarks ATMPs – EU ATMP development landscape and outlook ATMPs – ATMP update and Regulatory Strategy ATMPs – Nonclinical Challenges and Cases with ATMPs ATMPs – CMC Challenges and case studies with ATMPs ATMPs – The ATMP post approval path – patient and market access ATMPs – Riding the clinical trial rollercoaster – a patient’s perspective FCTAID – Patient First: changing the clinical trials paradigm IRI – Research infrastructures: Why do we need them? IRI – Covid – what can infrastructures do going forward IRI – Infrastructures Role in developing Personalized Health Potable water and biotechnologies Topic for the near future: Water microbiome Wastewater and Biotechnologies The future of the water sector: Matching needs and technologies Potable Water and Biotechnologies Wastewater and Biotechnologies Lunch and networking time The Future of the Water Sector – Matching Needs and Technologies Genomics and data to support personalised medicine (incl. registers/biobanks, biomarkers assessment) Discussion panel with Q&A from the audience Adoption of personalised medicine (incl. patient centricity, health technology assessment, regulations) Discussion panel with Q&A from the audience Personalised medicine – what the future brings? Discussion panel with Q&A from the audience Welcome and Opening of the Biotech Atelier Movement Health 2030: the Future of Healthcare The Innovative Health Initiative – Europe’s new public private partnership in health The Microbiome and Nutrigenetics Non-invasive Prenatal and Neonatal Testing Lifestyle and Health Advances Psychiatry: Pharmacogenetics and Personalised Practices Assisted reproductive technology (ART) Social freezing not cost effective to the society Problems with Using Polygenic Scores to Select Embryos Where are we now? Did CSV keep its promises? Advances in Diagnosis and Management of ATTR amyloid cardiomyopathy The Value of Patient Centricity – Why the Patient Voice is Essential Digital Health: Supporting Health Through Technologies Digital Solutions to Healthcare Problems HIV – The neglected pandemic Quality Assurance in a Molecualr Food Testing laboratory (an overview) Human Genetics in Favor of Reliable Diagnostics The Role of biomarkers in Personalised Medicine Precision medicine in daily routine, face reality Impact of access to biomarker test on the patient pathway Advantages of automated and digital Tissue Engineering and 3D cell cultivation Data Platforms for Digital Health DTx – AI as a medical device DTx – DTx in Cancer Treatment DTx – Health Equality Through Innovation DTx – DTx in Neuroscience The Potential of Gene Therapy for People with Rare Genetic Disorders Movement Health 2030 – Central and Eastern Europe (CEE) Movement Health 2030 – Bulgaria Wastewater and Antimicrobial Resistance The Concept and Value of Patient Advocacy My Stage IV Cancer Journey… And what helped me through it Towards a patient-centred approach in cancer care The value of patient advocacy in the field of oncology Prevention in Action – Cervical Cancer Cancer Registers – first steps: Armenia, Brazil and Kenya Pancreatic Cancer – increasing pancreatic cancer awareness Pain management – pancreatic cancer Inspire2Live and International Agency for Research in Cancer (IARC) partnership and collaboration Dicsussion and Conclusion Personalised Medicine and Patient Advocacy The Intersection of a Science Background and Patient Advocacy: How I Became a Better Advocate Don’t let Cancer become the Forgotten “C” in the Fight against COVID-19 COVID-19 vaccination for Cancer Patients How to fund your life science/biotech startup with non-dilutive funding Menopause and Employment – the Law AHT – HIV – the Neglected Pandemic AHT – Human Genetics in Favor of Reliable Diagnostics AHT – Wastewater and Antimicrobial Resistance PM – The Microbiome and Nutrigenetics PM – Non-invasive Prenatal and Neonatal Testing PM – Lifestyle and Health Advances PM – Kip Olmstead Keynote PM – Psychiatry: Pharmacogenetics and Personalised Practices PM – Neurology: precision medicine and management AHT – Opening / Introduction CSV – Validating AI/ML Solutions CSV – CSV and Best Practices GATE – GATE Flagship project on Alzheimer Validating AI/ML Solutions Personalised Medicine – building bridges among patients, researchers, decision makers & industry GATE – GATE Data platform GATE – Privacy-preserving AI-based diagnostic tools for Alzheimer disease Panel discussion “Water Resources and Biotechnologies” Biohydrogel – Saving irrigation water and protecting crops from droughts Environmental taxes and Water discharge fees Panel discussion “Wastewater and Biotechnologies” Anaerobic treatment for wastewater Panel discussion “Artificial intelligence and Water” Developing a one health approach by using a multi-dimensional matrix Digital Mental Health in 2022 and beyond IHI: Europe’s New public-private partnership for health and innovation Human Genetics and Personalised Medicine Personalised medicine strategies and application: genomics and molecular medicine ATMPs – a promise for better health and care Biotech and Life Science Clusters – space for innovation, development and business Digital Female Health in 2022 DTx – KPIs, Growth, reach, conversion, active engagement DTx Leaders of the NORDICS Regulation of DTx in the NORDICS Challenges in Digital Mental Health DHL: support of business and R&D Welcome and Opening of the Biotech Atelier Healthcare in Europe: what does the future hold? FemTech Leaders and the Gender Health Gap ATMPs and Rare Diseases: Patient Access and Opportunities New Perspectives in Pharmacogenetics and Pharmacogenomics Patient Centrricity and Patient Advocacy – What is Behind the Terms Patient centric medicines’ development: advancing meaningful patient engagement in the life cycle of medicines for better health outcomes EUPATI European Patients’ Academy on Therapeutic Innovation Preferences – an evidence-based approach to include patient perspectives in medical decision-making Patient Centricity: the Perspective of Institutions and Initiatives Fireside Chat: Patient Advocacy – What Is It? All for One, One for All: Patient Advocacy in Different Disease Areas / Patient Advocacy – United around a Common Mission War On Cancer: the Community for Everyone Impacted by Cancer Patient Advocacy and Healthcare Industry – the Meeting Point Patient Centricity and Patient Advocacy: the Industry Perspective The Importance of Diversity, Equity, and Inclusion in Advocacy Groups and its Effect on Patient Access for Rare Diseases in the Hispanic Community Moving Beyond Population Averages: Patients’ Priorities for Advancing Personalized Medicine Digital Health and Therapeutics: The New Reality Delightful future of healthcare DTx Takeaways from Germany, UK, Belgium, NORDICS Demystifying Health Coaching: Why and how to leverage these behavior change agents to surround your DTx Love problem: solve, validate, iterate, repeat The global mental health crisis No patient left behind: digital health and health inequalities Implementing the EU digital health strategy Take a selfie, know your healthie Leveraging data for better health Connection in the loneliness pandemic Spurring DTx innovation – a cross-country take The European DTx policy coalition Maximizing Your ‘Attractiveness Quotient’ Digitalizing healthcare: putting the full puzzle together, Roche An advice to my younger self, HelloBetter How the Cloud, Machine Learning and High Performance Computing are transforming Healthcare and Life Sciences Innovation Learning to ride the Lion – Clinician to Entrepreneur Secret sauce for accelerating innovation Healing the unhealable wound Our own little secret, Grace.Health Collaboration & integration: together, stronger, Augmental Technologies Closing of Digital Therapeutics & Digital Health Opening Introduction, key notes EU-QPPV – legal background and qualifications for the QPPV role; PV System oversight The EU Pharmacovigilance System Master File (PSMF) Pharmacovigilance System Master File (PSMF) – annexes, local PSMF, summary Audits and inspections of PV system QPPV Oversight & Compliance Management Medical Devices: Innovations and Regulation Fair data in life sciences Seizing the Digital Biomarker in DTx: trends, applications and opportunities, Evocal Health Pharmas & DTx, a new business model paradigm How to DTx: Pharma & biotech options for engaging with digital therapeutics – buy, build or partner to build Water and antimicrobial resistance Residual antibiotics in water Keynote lecture “Antimicrobial resistance in water: explore, measure and monitor” by Maarten van Dongen, AMR Insights Wastewater treatment and water re-use Interview “Water and EU Regulations” Closing of “Water & Biotechnologies” Keynote lecture topic TBA
Skip to content 
